View Post

Neratinib Stands Out at SABCS 2021 in HER2-Mutant Metastatic Breast Cancer

In In The News by Barbara Jacoby

By: Caroline Seymour From: onclive.com Sara A. Hurvitz, MD, provides perspective on key research that was presented during the 2021 SABCS in HER2-positive metastatic breast cancer. Although findings from the 2021 San Antonio Breast Cancer Symposium (SABCS) were more practice affirming than practice changing, an interesting signal from the phase 2 SUMMIT trial (NCT01953926) suggests that traditional HER2-directed agents may …

View Post

Black Race Found to Be Strongest Predictor of Lymphedema After Axillary Lymph Node Dissection

In In The News by Barbara Jacoby

By: Kate O’Rourke From: clinicaloncolog Black race and use of neoadjuvant chemotherapy (NAC) are associated with higher rates of breast cancer–related lymphedema, according to the results of a prospective screening study. The study, presented at the 2021 San Antonio Breast Cancer Symposium (GS4-01), involved analysis of 276 patients with breast cancer undergoing axillary lymph node dissection (ALND) and radiation. Enrolled …

View Post

HER2CLIMB: Tucatinib Boosts OS in Breast Cancer Patients With Brain Mets

In In The News by Barbara Jacoby

By: Greg Laub From: medpagetoday.com — Updated results show 9-month survival benefit in those with active or untreated brain metastases At the virtual San Antonio Breast Cancer Symposium, researchers presented new data from an exploratory analyses from the pivotal HER2CLIMB trial. After an additional 15.6 months of follow-up, the overall survival (OS) benefit when tucatinib (Tukysa) was added to trastuzumab …

View Post

10 important studies you may have missed from San Antonio Breast Cancer Symposium

In In The News by Barbara Jacoby

From: healio.com Healio provided comprehensive coverage of this year’s San Antonio Breast Cancer Symposium. Content includes stories about potentially practice-changing research, as well as perspective from key opinion leaders who discuss the implications of the findings. Here are 10 important studies from the symposium that may be relevant to your practice: Elacestrant (Radius Health) improved outcomes compared with standard endocrine …

View Post

Year in Review: Panelists summarize key findings in breast cancer research in 2021

In In The News by Barbara Jacoby

From: sabcsmeetingnews.org Despite the ongoing challenges of COVID-19 over the past year, researchers in 2021 reported important progress and major discoveries in breast cancer. A panel of experts discussed some of the latest advances in early and advanced breast cancer, basic science, and translational research during the special session Year in Review on Friday, December 10 at SABCS 2021. Basic …

View Post

Breast Cancer Patients with Estrogen Receptor Mutations May Benefit from Early Switch to Fulvestrant/Palbociclib

In In The News by Barbara Jacoby

From: sabcsmeetingnews.org Among patients with hormone receptor-positive breast cancer treated with an aromatase inhibitor plus palbociclib, those who displayed a rising ESR1 mutation detected in their blood before disease progression doubled their median progression-free survival following a switch to fulvestrant plus palbociclib, according to results from the phase III PADA-1 clinical trial presented during Thursday’s General Session at SABCS 2021. …